Praxis Precision (PRAX) Medicines announced its business outlook and priorities for 2026. Key highlights: Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA; Multiple registrational readouts expected across vormatrigine, relutrigine and elsunersen in 2026; Strong balance sheet, with $1.5 billion in pro forma cash and investments; Combined peak revenue estimates for the four late-stage assets expected to exceed $20 billion
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision names Megan Sniecinski as COO
- Praxis Precision Medicines Announces Major Underwritten Equity Offering
- Praxis Precision 2.212M share Spot Secondary priced at $260.00
- Praxis Precision announces common stock and warrants offering, no amount given
- Praxis Precision price target raised to $460 from $315 at Needham